Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

[PR Newswire] – TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency’s (EMA’s) Committee for Medicinal Products … Read . . . → Read More: Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – FDA panel recommends approval for Amgen’s skin cancer immunotherapy Stock Update (NASDAQ:REGN): Regeneron Announces Upcoming 2015 Investor Conference Presentations Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron Announces Upcoming 2015 Investor Conference Presentations